Pan Arab Journal of Oncology - Arab Medical Association Against ...
Pan Arab Journal of Oncology - Arab Medical Association Against ...
Pan Arab Journal of Oncology - Arab Medical Association Against ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
21. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial<strong>of</strong> fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations inpatients with previously untreated metastatic colorectal cancer. J Clin Oncol2004;22:23-30.22. Salama JK, Mell LK, Schomas DA, et al: Concurrent chemotherapy andintensity-modulated radiation therapy for anal canal cancer patients: Amulticenter experience. J Clin Oncol 25:4581-4586, 2007.23. Berry SR, Van Cutsem E, Kretzschmar A, et al: Final efficacy results forbevacizumab plus standard first-line chemotherapies in patients withmetastatic colorectal cancer: First BEAT (abstract 4025). J Clin Oncol26(15S):184s, 2008.24. Hedrick E, Kozl<strong>of</strong>f M, Hainsworth J, et al: Safety <strong>of</strong> bevacizumab pluschemo-therapy as first-line treatment <strong>of</strong> patients with metastatic colorectalcancer: updated results from a large observational registry in the US(BRiTE) (abstract 3536). J Clin Oncol24(18S):155s,2006.25. Kozl<strong>of</strong>f M, Hainsworth J, Badarinath S, et al: Survival <strong>of</strong> patientswith metastatic CRC treated with bevacizumab in combination withchemotherapy: results from the BRiTE registry (abstract 375). Presentedat the 2007 Gastrointestinal Cancers Symp-osium; Orlando, Fla; January19-21, 2007.26. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis <strong>of</strong> efficacy:The addition <strong>of</strong> bevacizumab to fluorouracil/leucovorin improves survivalfor patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712,2005.27. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial <strong>of</strong>irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-linetreatment <strong>of</strong> metastatic colorectal cancer: results from the BICC-C study. JClin Oncol 25:4779-4786, 2007.28. Purdie DM, Berlin JD, Flynn PJ, et al: The safety <strong>of</strong> long-term bevacizumabuse: Results from the BRiTE observational cohort study (OCS) (abstract4103). J Clin Oncol 26(15S):203s, 2008.www.amaac.org <strong>Pan</strong> <strong>Arab</strong> <strong>Journal</strong> <strong>of</strong> <strong>Oncology</strong> | vol 6; issue 1 | March 2013 < 23
Change language